134 related articles for article (PubMed ID: 36302311)
1. Health-related quality of life is underestimated and underreported in phase III clinical trials in NSCLC.
Salomone F; Di Costanzo F; Pecoraro G; Viscardi G; Viggiano A; Napolitano F; Santaniello A; Formisano L; Bianco R; Servetto A
Lung Cancer; 2022 Dec; 174():36-44. PubMed ID: 36302311
[TBL] [Abstract][Full Text] [Related]
2. Analysis of phase III clinical trials in metastatic NSCLC to assess the correlation between QoL results and survival outcomes.
Servetto A; Di Maio M; Salomone F; Napolitano F; Paratore C; Di Costanzo F; Viscardi G; Santaniello A; Formisano L; Bianco R
BMC Med; 2023 Jul; 21(1):234. PubMed ID: 37400832
[TBL] [Abstract][Full Text] [Related]
3. Quality of life analysis in lung cancer: A systematic review of phase III trials published between 2012 and 2018.
Reale ML; De Luca E; Lombardi P; Marandino L; Zichi C; Pignataro D; Ghisoni E; Di Stefano RF; Mariniello A; Trevisi E; Leone G; Muratori L; La Salvia A; Sonetto C; Bironzo P; Aglietta M; Novello S; Scagliotti GV; Perrone F; Di Maio M
Lung Cancer; 2020 Jan; 139():47-54. PubMed ID: 31734586
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Health-Related Quality of Life Reporting in Phase III RCTs of Advanced Genitourinary Tumors.
Di Costanzo F; Napolitano F; Salomone F; Amato AR; Alberico G; Migliaccio F; Pecoraro G; Marra A; Crocetto F; Ruffo A; Scagliarini S; Rossetti S; Puglia L; Di Napoli M; Bianco R; Servetto A; Formisano L
Cancers (Basel); 2023 Dec; 15(23):. PubMed ID: 38067406
[TBL] [Abstract][Full Text] [Related]
5. Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: A systematic review.
Servetto A; Salomone F; Di Costanzo F; Iuliano R; Marandino L; Napolitano F; Santaniello A; De Placido P; De Placido S; Di Maio M; Formisano L; Bianco R
Crit Rev Oncol Hematol; 2022 Apr; 172():103649. PubMed ID: 35259486
[TBL] [Abstract][Full Text] [Related]
6. Assessing the methodological quality of quality-of-life analyses in first-line non-small cell lung cancer trials: A systematic review.
Waisberg F; Lopez C; Enrico D; Rodriguez A; Hirsch I; Burton J; Mandó P; Martin C; Chacón M; Seetharamu N
Crit Rev Oncol Hematol; 2022 Aug; 176():103747. PubMed ID: 35717006
[TBL] [Abstract][Full Text] [Related]
7. Effect of chemotherapy on quality of life in patients with non-small cell lung cancer.
Mannion E; Gilmartin JJ; Donnellan P; Keane M; Waldron D
Support Care Cancer; 2014 May; 22(5):1417-28. PubMed ID: 24563068
[TBL] [Abstract][Full Text] [Related]
8. A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer.
Tanvetyanon T; Soares HP; Djulbegovic B; Jacobsen PB; Bepler G
J Thorac Oncol; 2007 Dec; 2(12):1091-7. PubMed ID: 18090580
[TBL] [Abstract][Full Text] [Related]
9. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
10. Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016.
Marandino L; La Salvia A; Sonetto C; De Luca E; Pignataro D; Zichi C; Di Stefano RF; Ghisoni E; Lombardi P; Mariniello A; Reale ML; Trevisi E; Leone G; Muratori L; Marcato M; Bironzo P; Novello S; Aglietta M; Scagliotti GV; Perrone F; Di Maio M
Ann Oncol; 2018 Dec; 29(12):2288-2295. PubMed ID: 30304498
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy in stage IV (metastatic) non-small-cell lung cancer. Provincial Lung Disease Site Group.
Lopez PG; Stewart DJ; Newman TE; Evans WK
Cancer Prev Control; 1997; 1(1):18-27. PubMed ID: 9765723
[TBL] [Abstract][Full Text] [Related]
12. Systematic review of symptom control and quality of life in studies on chemotherapy for advanced non-small cell lung cancer: how CONSORTed are the data?
Pat K; Dooms C; Vansteenkiste J
Lung Cancer; 2008 Oct; 62(1):126-38. PubMed ID: 18395928
[TBL] [Abstract][Full Text] [Related]
13. Impact of targeted therapies in metastatic renal cell carcinoma on patient-reported outcomes: Methodology of clinical trials and clinical benefit.
Dos Santos M; Brachet PE; Chevreau C; Joly F
Cancer Treat Rev; 2017 Feb; 53():53-60. PubMed ID: 28073101
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy and safety of Aidi injection plus paclitaxel-based chemotherapy for advanced non-small cell lung cancer: A meta-analysis of 31 randomized controlled trials following the PRISMA guidelines.
Xiao Z; Wang C; Zhou M; Hu S; Jiang Y; Huang X; Li N; Feng J; Tang F; Chen X; Ding J; Chen L; Wang Y; Li X
J Ethnopharmacol; 2019 Jan; 228():110-122. PubMed ID: 30243827
[TBL] [Abstract][Full Text] [Related]
15. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
16. Kanglaite injection plus platinum-based chemotherapy for stage III/IV non-small cell lung cancer: A meta-analysis of 27 RCTs.
Huang X; Wang J; Lin W; Zhang N; Du J; Long Z; Yang Y; Zheng B; Zhong F; Wu Q; Ma W
Phytomedicine; 2020 Feb; 67():153154. PubMed ID: 31926475
[TBL] [Abstract][Full Text] [Related]
17. Quality of life assessment and reporting in colorectal cancer: A systematic review of phase III trials published between 2012 and 2018.
Lombardi P; Marandino L; De Luca E; Zichi C; Reale ML; Pignataro D; Di Stefano RF; Ghisoni E; Mariniello A; Trevisi E; Leone G; Muratori L; La Salvia A; Sonetto C; Leone F; Aglietta M; Novello S; Scagliotti GV; Perrone F; Di Maio M
Crit Rev Oncol Hematol; 2020 Feb; 146():102877. PubMed ID: 31981880
[TBL] [Abstract][Full Text] [Related]
18. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
Brahmer JR; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Zhang J; Lubiniecki GM; Deitz AC; Rangwala R; Reck M
Lancet Oncol; 2017 Dec; 18(12):1600-1609. PubMed ID: 29129441
[TBL] [Abstract][Full Text] [Related]
19. Elemene injection as adjunctive treatment to platinum-based chemotherapy in patients with stage III/IV non-small cell lung cancer: A meta-analysis following the PRISMA guidelines.
Wang X; Liu Z; Sui X; Wu Q; Wang J; Xu C
Phytomedicine; 2019 Jun; 59():152787. PubMed ID: 31005810
[TBL] [Abstract][Full Text] [Related]
20. Sickle Cell Disease and Quality of Life: An Evaluation of Reporting of Patient-Reported Outcomes in Randomized Controlled Trials.
Renner A; Love M; Garrett E; Douglas A; Kee M; Heigle B; Wise A; Ottwell R; Hartwell M; Vassar M
Hemoglobin; 2022 Sep; 46(5):265-268. PubMed ID: 36268837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
